| | Pfizer announced the M&A event of the year with its Biohaven acquisition. Top investors turned to Tegus for on-demand insight on Nurtec’s trajectory, Biohaven’s leadership, and the competitive environment. See for yourself with a free Tegus trial. |
One year into Philips' ventilator foam recall, FDA tallies 124 deaths, 21,000 complaints Most influential people in biopharma—the regulators and advocates Calling all Fierce 15 fans: Nominations for the 2022 Fierce Biotech Fierce 15 are now open Mayo Clinic posts $227M net loss for Q1 as labor expenses shoot up Sanofi's Dupixent scores big as the first FDA-approved treatment for eosinophilic esophagitis A vibrating pill for constipation heads to the FDA after completing phase 3 study BCBS of Massachusetts launches health equity business incubator Biohaven flunks first clinical test for rare disease drug post-Pfizer sell-off GSK dodges UK strike with improved pay offer for staffers Fractyl shows its intestine-resurfacing device for Type 2 diabetes improves insulin resistance, pancreatic function HHS announces $1.5B grant for states to address ongoing opioid epidemic Precision BioSciences makes case for 2 gene editing programs over CRISPR with preclinical data GE Healthcare signs up to distribute HistoSonics’ soundwave therapy for liver cancer Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial Featured Story | By Andrea Park In the first year since Philips began taking precautions against a suspected safety issue with many of its ventilators and CPAP and BiPAP machines last April, the issue has sparked more than 21,000 complaints including reports of cancer, pneumonia, asthma, infection, headache, nodules, and chest pain as well as more than 120 deaths. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky,Annalee Armstrong,Max Bayer,Angus Liu As the biopharma industry develops increasingly specialized treatments, regulators are being forced to adapt. And at the same time, the industry is making strides toward becoming more inclusive. These are the most influential regulators and advocates in biopharma. read more By Annalee Armstrong Fierce Biotech is once again seeking your nominations for the best, most exciting and innovative private biotechs. read more By Robert King Mayo Clinic posted a $227 million net loss for the first quarter of 2022 as the system faced major headwinds from rising labor expenses to a volatile investment market. read more By Zoey Becker Patients with eosinophilic esophagitis have been suffering with no hope for relief as there are no FDA-approved treatments for the disease. That's now changed with an FDA nod for Sanofi's Dupixent. read more By Conor Hale Vibrant Gastro is putting forward its novel approach as a completely drug-free alternative to treatments for infrequent or difficult bowel movements. read more By Cameron Evans Blue Cross Blue Shield of Massachusetts launched a new program that will provide financial, strategic and mentorship support to startup founders of color focused on creating equitable healthcare services and solutions. read more By Max Bayer Biohaven reported that troriluzole has failed a phase 3 trial in spinocerebellar ataxia, just weeks after CEO Vlad Coric, M.D., touted the company's future as a slimmed-down R&D engine after the migraine business was sold off to Pfizer for $11.6 billion. read more By Fraiser Kansteiner A potential strike by more than 1,000 GSK engineers, technicians, lab analysts, warehouse workers and others has been called off after the employees—represented by Britain and Ireland’s biggest labor union Unite—accepted an improved pay offer from the British Big Pharma. read more By Conor Hale The Revita DMR outpatient procedure strips out and helps reset the small intestine's lining, which can thicken over years from dietary fats, sugars and other foods. read more By Anastassia Gliadkovskaya The program’s goal, according to the announcement, is to develop care services and improve outcomes. read more By Max Bayer Precision BioSciences boasted two sets of early preclinical data of its gene editing platform at ASGCT, making its case over CRISPR. Notably, the company said it was able to make an insertion in the genome in non-human primates using its treatment for ornithine transcarbamylase deficiency. read more By Conor Hale Pending FDA approval, HistoSonics will use guided sonic beams to deliver vibrations into the organ without breaking the skin, causing the targeted tissue to break down and liquify. read more By Nick Paul Taylor Concert Pharmaceuticals has hit the high notes in a phase 3 alopecia areata clinical trial, finding 41.5% of people had at least 80% scalp hair coverage after taking the high dose of its JAK inhibitor. The data put Concert in the wings as Eli Lilly and Pfizer prepare to take to the stage and compete for the market. read more |
